Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Number of JP Drugs to Increase by 84
May 21, 2007
- Teijin: Pharm. Sales Up 7.1% to \113.1 Bil.
May 21, 2007
- Nippon Shinyaku Establishes Technology to Manufacture Long RNA Oligomers
May 21, 2007
- Kaken: Main Products Drive Overall Business
May 21, 2007
- Korosho to Select 10 Chukaku Hospitals, 30 Kyoten Hospitals for Clinical Trials
May 21, 2007
- Torii: Both Sales, Profits Down Due to Slump of Main Products
May 21, 2007
- R&D NEWS IN BRIEF
May 21, 2007
- Olympus: Sales Exceed \1 Tri. with 57.9% Increase in Operating Profits
May 21, 2007
- JT: Sales Down 7.7%, Operating Loss of \11.2 Bil.
May 21, 2007
- HuBit Genomix Begins New Gene Genome Analysis Service Jointly with deCODE
May 21, 2007
- Asahi Kasei Pharma: License Fee on Fasudil Props Up Sales
May 21, 2007
- MEDICAL DEVICE NEWS IN BRIEF
May 21, 2007
- Nissan Chemical, Taisho License NM-702 to Milford
May 21, 2007
- On-Line Medical Bill Processing Starting
May 21, 2007
- GSK Recommences Supply of Relenza
May 21, 2007
- JSC to Start Antibacterial Chemotherapy Specialist Certification System
May 21, 2007
- Quintiles Receives Increasing Number of Orders on ECG Analysis Services
May 21, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 21, 2007
- Korosho Continues Hearings to Increase Price Agreement Rates
May 21, 2007
- 5-Year Strategy to Develop Innovative Drugs, Med. Devices Proposed
May 14, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…